The Berlin Heart EXCOR® is a mechanical, pulsatile ventricular assist device. The paracorporeal assist device is pneumatically driven and can be used for long-term bridging therapy of one or both ventricles (LVAD, BIVAD, RVAD). It is specifically designed for pediatric patients and can be used in neonates as well as juveniles and adults. The infant presented in this video tutorial was diagnosed with myocarditis leading to end-stage heart failure and severe mitral valve regurgitation. A bridging therapy was indicated and a Berlin Heart EXCOR® VAD was implanted. This tutorial provides detailed insight on how to perform this procedure. In addition, a safe and effective way of extending the outflow cannula is demonstrated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1510/mmcts.2020.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Left Ventricular Size on Outcomes Following HeartMate 3 Left Ventricular Assist Device Implantation: Analysis of the European Registry for Patients With Mechanical Circulatory Support (EUROMACS).
ASAIO J
December 2024
Cleveland Clinic Florida, Heart, Vascular and Thoracic Institute, Advanced Heart Failure Program, Weston, Florida.
We investigated the association of preimplant left ventricular end-diastolic diameter (LVEDD) with outcomes after HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation. Patients from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) registry who underwent HM3 implantation from August 2014 to February 2023 (n = 834) were analyzed according to preoperative LVEDD: less than or equal to 65 (n = 251), 65-80 (n = 441), and greater than or equal to 80 mm (n = 142). The mean age was 54.
View Article and Find Full Text PDFC-Reactive Protein Levels and Outcomes in Infarct-Related Cardiogenic Shock: Data from the ECLS-SHOCK Trial.
Eur Heart J Acute Cardiovasc Care
December 2024
Department of Cardiology, Angiology, Hemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Background: The impact of systemic inflammation in acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is still a matter of debate. The present ECLS-SHOCK sub-study investigates the association of C-reactive protein (CRP) levels with short-term outcomes in patients with AMI-CS.
Methods: Patients with AMI-CS enrolled in the multicenter, randomized ECLS-SHOCK trial between 2019 and 2022 were included.
Predictors and outcomes in patients undergoing surgery for acute type A aortic dissection requiring concomitant veno-arterial extracorporeal membrane oxygenation support-a retrospective multicenter cohort study.
Eur J Cardiothorac Surg
December 2024
University Clinic for Cardiac Surgery, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Objectives: The study aim was to investigate the outcomes and risk factors for mortality in patients undergoing surgery for acute type A aortic dissection (ATAAD) receiving concomitant veno-arterial extracorporeal membrane oxygenation (ECMO) support.
Methods: Patients from five European centers who underwent surgery for ATAAD and received perioperative veno-arterial ECMO support were included. A multivariable binary logistic regression analysis was performed to identify risk factors for thirty-day mortality.
Hospitalized upper extremity artery disease patients: treatment and long-term outcomes.
Eur Heart J
December 2024
Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
Background And Aims: Current knowledge about upper extremity artery disease (UEAD) is scarce. This study aimed to evaluate the prevalence, treatment patterns, and short- and long-term outcomes of patients suffering from UEAD.
Methods: Retrospective health claims data of patients who were hospitalized with a primary diagnosis of UEAD between 2010 and 2017 were analysed.
CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.
Allergy
January 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.
Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!